Logo image of NRXS

NEURAXIS INC (NRXS) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:NRXS - US64134X2018 - Common Stock

4.51 USD
+0.31 (+7.38%)
Last: 12/30/2025, 8:04:00 PM
4.51 USD
0 (0%)
Pre-Market: 12/31/2025, 8:49:33 AM
Fundamental Rating

3

Taking everything into account, NRXS scores 3 out of 10 in our fundamental rating. NRXS was compared to 186 industry peers in the Health Care Equipment & Supplies industry. The financial health of NRXS is average, but there are quite some concerns on its profitability. NRXS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

NRXS had negative earnings in the past year.
NRXS had a negative operating cash flow in the past year.
In the past 5 years NRXS always reported negative net income.
NRXS had a negative operating cash flow in each of the past 5 years.
NRXS Yearly Net Income VS EBIT VS OCF VS FCFNRXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

NRXS's Return On Assets of -110.11% is on the low side compared to the rest of the industry. NRXS is outperformed by 82.80% of its industry peers.
With a Return On Equity value of -183.49%, NRXS is not doing good in the industry: 71.51% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -110.11%
ROE -183.49%
ROIC N/A
ROA(3y)-1140.93%
ROA(5y)-815%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRXS Yearly ROA, ROE, ROICNRXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

Looking at the Gross Margin, with a value of 84.82%, NRXS belongs to the top of the industry, outperforming 93.55% of the companies in the same industry.
In the last couple of years the Gross Margin of NRXS has grown nicely.
NRXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.51%
GM growth 5YN/A
NRXS Yearly Profit, Operating, Gross MarginsNRXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -200 -400

6

2. Health

2.1 Basic Checks

NRXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NRXS has more shares outstanding
The debt/assets ratio for NRXS has been reduced compared to a year ago.
NRXS Yearly Shares OutstandingNRXS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M
NRXS Yearly Total Debt VS Total AssetsNRXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

NRXS has an Altman-Z score of -3.98. This is a bad value and indicates that NRXS is not financially healthy and even has some risk of bankruptcy.
NRXS has a Altman-Z score of -3.98. This is in the lower half of the industry: NRXS underperforms 66.67% of its industry peers.
There is no outstanding debt for NRXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.98
ROIC/WACCN/A
WACC8.79%
NRXS Yearly LT Debt VS Equity VS FCFNRXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

2.3 Liquidity

A Current Ratio of 2.82 indicates that NRXS has no problem at all paying its short term obligations.
NRXS's Current ratio of 2.82 is in line compared to the rest of the industry. NRXS outperforms 54.30% of its industry peers.
A Quick Ratio of 2.76 indicates that NRXS has no problem at all paying its short term obligations.
The Quick ratio of NRXS (2.76) is better than 63.44% of its industry peers.
Industry RankSector Rank
Current Ratio 2.82
Quick Ratio 2.76
NRXS Yearly Current Assets VS Current LiabilitesNRXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

4

3. Growth

3.1 Past

NRXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.66%, which is quite impressive.
NRXS shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.77%.
NRXS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.42% yearly.
EPS 1Y (TTM)66.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
Revenue 1Y (TTM)41.77%
Revenue growth 3Y-0.42%
Revenue growth 5YN/A
Sales Q2Q%46.57%

3.2 Future

Based on estimates for the next years, NRXS will show a very negative growth in Earnings Per Share. The EPS will decrease by -32.00% on average per year.
Based on estimates for the next years, NRXS will show a quite strong growth in Revenue. The Revenue will grow by 14.08% on average per year.
EPS Next Y-890%
EPS Next 2Y-137.7%
EPS Next 3Y-32%
EPS Next 5YN/A
Revenue Next Year-70.39%
Revenue Next 2Y-16.11%
Revenue Next 3Y14.08%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NRXS Yearly Revenue VS EstimatesNRXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
NRXS Yearly EPS VS EstimatesNRXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NRXS. In the last year negative earnings were reported.
Also next year NRXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRXS Price Earnings VS Forward Price EarningsNRXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRXS Per share dataNRXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

NRXS's earnings are expected to decrease with -32.00% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-137.7%
EPS Next 3Y-32%

0

5. Dividend

5.1 Amount

NRXS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

NEURAXIS INC

NYSEARCA:NRXS (12/30/2025, 8:04:00 PM)

Premarket: 4.51 0 (0%)

4.51

+0.31 (+7.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)03-20 2026-03-20
Inst Owners13.4%
Inst Owner Change-4.19%
Ins Owners18.9%
Ins Owner Change-37.65%
Market Cap48.03M
Revenue(TTM)3.22M
Net Income(TTM)-7.80M
Analysts82.5
Price Target5.99 (32.82%)
Short Float %2.05%
Short Ratio0.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.01%
Min EPS beat(2)-34.8%
Max EPS beat(2)-5.21%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-55.37%
Min Revenue beat(2)-99.88%
Max Revenue beat(2)-10.86%
Revenue beat(4)0
Avg Revenue beat(4)-67.3%
Min Revenue beat(4)-99.88%
Max Revenue beat(4)-10.86%
Revenue beat(8)0
Avg Revenue beat(8)-69.11%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-11.86%
EPS NY rev (3m)-11.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.09%
Revenue NY rev (1m)-13.06%
Revenue NY rev (3m)-19.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.93
P/FCF N/A
P/OCF N/A
P/B 11.29
P/tB 11.54
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.3
BVpS0.4
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -110.11%
ROE -183.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.82%
FCFM N/A
ROA(3y)-1140.93%
ROA(5y)-815%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.51%
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.14%
Cap/Sales 0.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.82
Quick Ratio 2.76
Altman-Z -3.98
F-Score4
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)133.32%
Cap/Depr(5y)94.99%
Cap/Sales(3y)2.06%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
EPS Next Y-890%
EPS Next 2Y-137.7%
EPS Next 3Y-32%
EPS Next 5YN/A
Revenue 1Y (TTM)41.77%
Revenue growth 3Y-0.42%
Revenue growth 5YN/A
Sales Q2Q%46.57%
Revenue Next Year-70.39%
Revenue Next 2Y-16.11%
Revenue Next 3Y14.08%
Revenue Next 5YN/A
EBIT growth 1Y17.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1096.17%
EBIT Next 3Y-16.84%
EBIT Next 5YN/A
FCF growth 1Y-160.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.44%
OCF growth 3YN/A
OCF growth 5YN/A

NEURAXIS INC / NRXS FAQ

What is the fundamental rating for NRXS stock?

ChartMill assigns a fundamental rating of 3 / 10 to NRXS.


What is the valuation status for NRXS stock?

ChartMill assigns a valuation rating of 0 / 10 to NEURAXIS INC (NRXS). This can be considered as Overvalued.


What is the profitability of NRXS stock?

NEURAXIS INC (NRXS) has a profitability rating of 1 / 10.